ABSTRACT A new levofloxacin derivative using silver triflate with antibacterial activity was synthesized and characterized. The new compound has been physicochemically characterized through elemental analysis, spectroscopic and thermal methods. All correlated experimental data suggested that the levofloxacin triflate was obtained. The antibacterial activity of the new compound was tested against six Gram-positive and Gram-negative bacteria. In vitro, the new compound had similar activity to levofloxacin against Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae and very closed to the minimum inhibitory concentration values of levofloxacin against Staphylococcus aureus MRSA, Enterococcus faecalis, and Pseudomonas aeruginosa.

BACKGROUND The link between Candida albicans and diabetes mellitus is well-acknowledged, but incompletely elucidated. OBJECTIVES The purpose of this study is to assess the growth rate of C. albicans (CA) in the presence of different concentrations of glucose and fructose, two of the main pathophysiologic and nutritionally relevant sugars in diabetic patients, in order to obtain a better understanding of the nutrient acquisition strategy and its possible relation to the hyperglycemic status of diabetic patients. METHODS The effects of different concentrations of glucose and fructose (1000 mg%, 500 mg%, 250 mg% and 100 mg% w/v) on the growth rate of CA have been studied by flow-cytometry. FINDINGS We found that glucose concentration is directly related to CA growth, which may be linked to the frequent yeast infections that occur in non-controlled diabetic patients; we also show that fructose inhibits CA growth rate. MAIN CONCLUSIONS As a consequence of our hypothesis, the study demonstrates that fructose-containing food may prevent the development of candidiasis, at least in oral sites.